ReviewAnnals of joint2026
Treatment options for concomitant cartilage damage in the anterior cruciate ligament (ACL)-injured athlete.
Review in Annals of joint, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute anterior cruciate ligament (ACL) tears are common in athletes and frequently occur with concomitant cartilage injuries, which can significantly impact knee function and return-to-sport outcomes. Professional athletes have a higher prevalence of ACL injuries with associated chondral lesions, compared with nonprofessional athletes. Management of ACL injuries with concurrent cartilage damage requires careful consideration of operative versus nonoperative treatment, timing, surgical technique, and the extent of cartilage involvement. The objective of this study is to review and compare treatment strategies for concomitant chondral lesions in ACL-injured athletes, with emphasis on return-to-sport outcomes, functional results, and long-term durability. Nonoperative measures include nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and activity modification. Surgical management strategies are tailored to high-demand athletes and have demonstrated improved outcomes with return-to-sport rates consistent with positive functional recovery. Arthroscopic debridement offers short-term symptom relief, while microfracture provides fibrocartilage repair but demonstrates lower long-term durability and return-to-sport rates. Osteochondral autograft transplantation (OAT) and osteochondral allograft transplantation (OCA) techniques restore hyaline cartilage and show superior functional outcomes and higher return-to-sport rates, particularly for larger defects. Cell-based therapies, including autologous chondrocyte implantation (ACI) and matrix-induced ACI (MACI), combined with ACL reconstruction (ACLR), have been associated with improved clinical results for symptomatic chondral lesions, with comparable outcomes to isolated procedures. Cell-based therapies limit damage to the subchondral bone plate but do require maturation of the repair tissue to be effective. Procedures such as high tibial or distal femoral osteotomy (DFO) correct malalignment and can improve graft and cartilage durability. Biologic augmentation with platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC) represents an emerging strategy to enhance cartilage healing and patient-reported outcomes (PROMs). Of these treatment modalities, OAT and OCA procedures demonstrated the fastest return-to-sport rates when compared with other surgical options, including debridement and microfracture. Long-term durability was highest in patients treated with OAT and ACI. Overall, treatment of chondral lesions in ACL-injured athletes requires individualized strategies that balance functional recovery, durability of repair, and timing of return to play, with evolving techniques that demonstrate trends toward improved long-term outcomes and joint preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.